Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) – Equities researchers at Cantor Fitzgerald upped their FY2019 earnings estimates for Spring Bank Pharmaceuticals in a report released on Tuesday, March 12th. Cantor Fitzgerald analyst E. Piros now expects that the company will earn ($1.90) per share for the year, up from their previous forecast of ($2.40). Cantor Fitzgerald has a “Buy” rating and a $34.00 price objective on the stock.
Several other equities analysts have also weighed in on the stock. Chardan Capital set a $45.00 price objective on shares of Spring Bank Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, November 30th. Zacks Investment Research lowered shares of Spring Bank Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday. One investment analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $28.80.
NASDAQ:SBPH opened at $10.85 on Friday. Spring Bank Pharmaceuticals has a twelve month low of $8.14 and a twelve month high of $15.73. The stock has a market cap of $178.34 million, a PE ratio of -5.80 and a beta of 0.80.
Spring Bank Pharmaceuticals (NASDAQ:SBPH) last posted its quarterly earnings data on Monday, March 11th. The company reported ($0.33) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.50) by $0.17.
A number of hedge funds have recently bought and sold shares of the business. Northern Trust Corp lifted its stake in Spring Bank Pharmaceuticals by 0.9% during the fourth quarter. Northern Trust Corp now owns 171,750 shares of the company’s stock valued at $1,785,000 after buying an additional 1,507 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in Spring Bank Pharmaceuticals by 5.9% during the fourth quarter. Bank of New York Mellon Corp now owns 43,789 shares of the company’s stock valued at $454,000 after buying an additional 2,430 shares in the last quarter. Rhumbline Advisers lifted its stake in Spring Bank Pharmaceuticals by 65.3% during the fourth quarter. Rhumbline Advisers now owns 16,771 shares of the company’s stock valued at $174,000 after buying an additional 6,623 shares in the last quarter. Geode Capital Management LLC lifted its stake in Spring Bank Pharmaceuticals by 8.7% during the fourth quarter. Geode Capital Management LLC now owns 116,861 shares of the company’s stock valued at $1,214,000 after buying an additional 9,398 shares in the last quarter. Finally, Blair William & Co. IL purchased a new stake in Spring Bank Pharmaceuticals during the third quarter valued at about $123,000. 43.18% of the stock is owned by institutional investors.
Spring Bank Pharmaceuticals Company Profile
Spring Bank Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics using small molecule nucleic acid hybrid (SMNH) chemistry platform. The company's lead SMNH product candidate is inarigivir soproxil, for the treatment of chronic hepatitis B virus (HBV).
See Also: Fundamental Analysis
Receive News & Ratings for Spring Bank Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.